

May 26, 2003
Shionogi & Co., Ltd.

Shionogi Signs Licensing Agreement with Peninsula Pharmaceuticals, Inc. of the U.S.

Shionogi & Co., Ltd. has announced the conclusion of a licensing agreement with Peninsula Pharmaceuticals, Inc. of Alameda, California that will transfer to Peninsula the rights for Shionogi's proprietary compound S-4661 (generic name: doripenem).

Shionogi has completed phase 3 pivotal trials of S-4661, a carbapenem antibiotic created by Shionogi, and is preparing to submit an NDA to the Japan MHLW later this year. Shionogi entered into the contract for overseas development and marketing of S-4661 to make effective use of its assets and to further expand its international presence, a goal of the company's medium-term management plan.

Peninsula, a private, venture backed company, focuses its business on treatments for infectious diseases, and has numerous specialists in development and marketing. Shionogi therefore judged Peninsula to be a firm well suited for the development of S-4661.

Exclusive rights, including sublicense rights, for the development, import, use and sales of S-4661 in North America will be transferred from Shionogi to Peninsula under the agreement.

[For reference]

Company Profile

Company name:	Peninsula Pharmaceuticals, Inc.
Headquarters:	Alameda, California
Number of Employees:	12
Representative:	Paul F. Truex, President
Type of Business:	Pharmaceutical Development

[For further information]

Shionogi Contact

Head Office(Osaka, Japan)	Public Relations
Phone: +81-6-6209-7885	Fax: +81-6-6229-9596
Tokyo Branch Office(Tokyo)	Public Relations
Phone: +81-3-3406-8164	Fax: +81-3-3406-8099